

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<b>Licensee</b> 1. Bronson Methodist Hospital  2. 601 John St. Kalamazoo, MI 49007		In accordance with application dated January 16, 2021,  3. License No.: 21-13125-01 is amended in its entirety to read as follows:	4. Expiration Date: March 31, 2021  5. Docket No.: 030-02146 Reference No.:
6. Byproduct, source, and/or special nuclear material  A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 31.11	7. Chemical and/or physical form  A. Any B. Any C. Any D. Prepackaged Kits	8. Maximum amount that licensee may possess at any one time under this license  A. As Needed B. As Needed C. 2 curies total D. 10 millicuries total	9. Authorized use  A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For use in in-vitro studies.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-13125-01

Docket or Reference No.:  
030-02146

Amendment No. 73

- |   |  |  |   |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form   | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use   |
| E. Yttrium-90 permitted by 10 CFR 35.1000             | E. Microspheres (Sirtex Wilmington LLC, Sirtex Medical Limited, or ANSTO Radiopharmaceuticals and Industrials, Model SIR-Spheres microspheres) | E. 1 curie total   | E. For medical use as permitted by 10 CFR 35.1000 in a Sirtex Wilmington LLC SIR-Spheres delivery system.   |
| F. Yttrium-90 permitted by 10 CFR 35.1000             | F. Microspheres (Nordion (Canada), Inc. (formerly MDS Nordion), Model TheraSphere glass microsphere)   | F. 2 curies total  | F. For medical use as permitted by 10 CFR 35.1000 in a Nordion (Canada), Inc. (formerly MDS Nordion) TheraSphere glass microsphere dose delivery system |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-13125-01

Docket or Reference No.:  
030-02146

Amendment No. 73

**CONDITIONS**

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.F. may be used at the licensee's facilities located at 601 John St., Kalamazoo, Michigan 49007 and 252 E. Lovell St., Kalamazoo, Michigan 49007.
- B. Licensed material listed in Subitem Nos. 6.A. and 6.B. may be used at the licensee's facilities located at 408 Hazen St., Paw Paw, Michigan 49079.
- C. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at the licensee's facilities located at 955 S. Bailey St., South Haven, Michigan 49090.
11. The Radiation Safety Officer (RSO) for this license is Laura T. Speer Smith, M.S.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u>  |
|---|--|
| Evalt Ayerdi, M.D.                        | 10 CFR 35.100, 10 CFR 35.200   |
| George J. Balogh, M.D.                    | 10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200                             |
| Ruggero Battan, M.D.                      | 10 CFR 35.300  |
| Joseph A. Borrello, M.D.                  | 10 CFR 35.100, 10 CFR 35.200   |
| William B. Campbell, M.D.                 | 10 CFR 35.100, 10 CFR 35.200   |
| Theodore J. Cunningham, M.D.              | 10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200                             |
| Michael G. Doherty, M.D.                  | 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres and TheraSpheres) |
| Brett J. Eliuk, D.O.                      | 10 CFR 35.100, 10 CFR 35.200   |
| Andrew Forsyth, M.D.                      | 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)                  |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-13125-01

Docket or Reference No.:  
030-02146

Amendment No. 73

Authorized User (M.D., D.O., etc.)Material and Use

John A. Freeby, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Gary Frick, M.D.

10 CFR 35.100, 10 CFR 35.200

Bruce D. Goethe, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Charles Gregory Hodgeman, M.D.

10 CFR 35.100, 10 CFR 35.200

Christina V. Jacobs, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Todd Johnson, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Robert H. Jongeward, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Thomas A. Keller Jr., M.D.

10 CFR 35.100, 10 CFR 35.200

Arthur C. Laurell, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Craig Moore, M.D.

10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres and TheraSpheres)

Douglas D. Notman, M.D.

10 CFR 35.300

Robert Oostveen, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Michael Pack, D.O.

10 CFR 35.100, 10 CFR 35.200

Michael S. Pawlik, D.O.

10 CFR 35.100, 10 CFR 35.200

Eric William Payne, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Joel H. Reinoehl, M.D.

10 CFR 35.200

Christopher Rogers, D.O.

10 CFR 35.100, 10 CFR 35.200

John Schonder, M.D.

10 CFR 35.100, 10 CFR 35.200

Matthew A. Smetts, M.D.

10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Patrick A. Sorek, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Manish K. Varma, M.D.

10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres and TheraSpheres)

Robert A. Williams, D.O.

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-13125-01

Docket or Reference No.:  
030-02146

Amendment No. 73

Authorized User (M.D., D.O., etc.)

Douglas J. Wunderly, M.D.

Robert Zick, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to iodine-131 for imaging and localization studies)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 1, 2010 (ML102770091)
- B. Letter dated March 3, 2011 (ML110890477)
- C. Letter dated March 8, 2011 (ML110890491)
- D. Letter dated March 16, 2012 (ML120760432)
- E. Letter dated May 14, 2012 (ML12135A662)
- F. Letter dated December 3, 2015 (ML15338A089)
- G. Letter dated April 29, 2016 (ML16123A188)
- H. Letter dated August 2, 2016 (ML16218A420)
- I. Letter dated August 4, 2016 (ML16223A952)
- J. Letter dated August 31, 2016 (ML16245A378)

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-13125-01

Amendment No. 73

Docket or Reference No.:  
030-02146

- K. Letter dated October 19, 2016 (ML16293A954)
- L. Application dated December 27, 2018 (ML19056A063)
- M. Letter dated August 22, 2019 (ML19235A234)
- N. Letter dated October 17, 2019 (ML19296A861)
- O. Application dated January 16, 2021 (ML21020A048)
- P. Letter dated February 22, 2021 (ML21069A229)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 10, 2021By: \_\_\_\_\_  
Magdalena R. Gryglak  
Region 3